9 月 25 日，CDE 官网显示，乐普生物的 EGFR ADC 维贝柯妥塔单抗（MRG003）申报上市，用于既往经至少二线系统化疗和 PD-1/PD-L1 抑制剂治疗失败的复发/转移性鼻咽癌患者。

ADC作为新一代的药物，2019年后，如雨后春笋般接连获批上市，2021年荣昌生物爱地希的获批上市标志着国产ADC创新药开发也迎来里程碑，之后中国企业在ADC赛道的研发热火朝天地推进着。

欢迎关注凯莱英药闻今日，根据中国国家药监局药品审评中心（CDE）官网公示，乐普生物的注射用维贝柯妥塔单抗的上市申请获得受理，用于既往经至少二线系统化疗和 PD-1/PD-L1 ...

题图 | PixabayBC3195是智康弘义开发的新一代靶向CDH3的抗体偶联药物，该产品采用与CDH3蛋白具有较高亲和力并展现出良好内吞活性的抗体，同时采用经临床验证、具有“旁观者效应”的连接子和有效载荷vc-MMAE，以进一步提高临床开发成功率 ...

Reference: DOI: 10.4155/bio.12.299. Image Credit: Sino Biological Inc. Immobilized MMAE-ADC at 1 μg/mL (100 μL/well) can bind the Anti-MMAE Antibody, the EC₅₀ of Anti-MMAE is 50 -1000 ng/mL.

毕竟每年的世界冠军都是最能适应版本改动的队伍，而在今年的夏季赛中，ADC中单成为了赛场主流，即使到了季后赛版本也是如此。然而在世界赛 ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Each of these inter-related components of the ADC is important for optimal ADC activity. ADCs allow for the delivery of cytotoxic agents that are too toxic when administered systemically to tumors ...

China’s National Medical Products Administration (NMPA) has accepted NDAs for Innovent Biologics Inc.’s IL-23p19 antibody picankibart to treat moderate to severe plaque psoriasis, and Lepu Biopharma’s ...

Scientists and doctors are getting much better at developing treatments for cancer. More than 18 million people with a history of cancer were alive in the U.S. at the beginning of 2022, up from just 3 ...

we feel that we have a novel and differentiated ADC to target Nectin-4 in the broad panel of tumor indication on top of bladder cancer by overcoming the challenges associated with Nectin-4, MMAE ...